MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • Noticias
  • Store
  • Corredores
  • Descargar
  • Calendario económico
  • Señales Comerciales
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Italiano Italiano
  • Türkçe Türkçe
Supernus Pharmaceuticals, Inc.

SUPN

#1407
Supernus Pharmaceuticals, Inc.
54.7300
+0.48%
Sector:
Básica:
Profit Currency:
Rango diario
54.7300
54.7300
Rango anual
43.1100
59.6800
Cambio diario
+0.48%
Monthly Change
+10.77%
6 month change
+1.35%
Cambio anual
+1.35%
Cierres anteriores
54.4700
Open
54.7300
Bid
Ask
Low
54.7300
High
54.7300
Volumen
97
  1. Markets
  2. Acciones
  3. Atención Sanitaria
  4. SUPN
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Noticias

Investing Investing
SUPN
2026.02.25
TD Cowen relève l’objectif de cours de Supernus Pharmaceuticals suite au relancement d’Onapgo
Investing Investing
SUPN
2026.02.25
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch
Investing Investing
SUPN
2026.02.25
L’action Supernus Pharmaceuticals atteint un sommet de 52 semaines à 57,76$
Investing Investing
SUPN
2026.02.25
Supernus Pharmaceuticals stock hits 52-week high at $57.76
Investing Investing
SUPN
2026.02.25
Cantor Fitzgerald réitère sa note de surpondération sur Supernus grâce aux gains d’approvisionnement
Investing Investing
SUPN
2026.02.25
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
Zacks Zacks
SUPN ASMB
2026.02.25
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Investing Investing
SUPN
2026.02.24
Le BPA de Supernus a manqué les attentes de 0,48$, le CA a surpassé les prévisions
Investing Investing
SUPN
2026.02.24
Supernus earnings missed by $0.48, revenue topped estimates
Investing Investing
SUPN
2026.02.24
Supernus face au test des résultats après le choc de rentabilité du T3
Investing Investing
SUPN
2026.02.24
Supernus faces earnings test after Q3 shock to profitability
Zacks Zacks
SUPN BBIO
2026.02.17
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline

Markets

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Charts & Ideas

  • Ideas comerciales
  • Ideas ilustrativas
  • Gráfico

MQL5 Community

  • Market
  • Señales
  • Foro
  • Artículos
  • CodeBase

Noticias

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Corredores

  • Todos los brókeres
  • Fórex
  • Acciones
  • Metales
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Información y contacto Legal
Copyright 2000-2026, MetaQuotes Ltd